If you are interested in discussing Wegovy^®, a prescription-only medicine, with your healthcare provider (HCP), we suggest you do so in the coming months as we continue to fill the supply chain. To determine if your insurance plan covers Wegovy^®, you can visit Wegovy.com beginning January 3, 2023 or contact your insurance provider.

We take our responsibility to meet the needs of people living with obesity very seriously and ensuring supply is available is a top priority. 

While production is ongoing, the overall demand for this medicine is still uncertain and will continue to be assessed. We will closely monitor prescribing trends and phase promotional efforts as we assess demand.

We are taking significant measures to increase our production capacity for the long-term. In the first half of 2023, a second contract manufacturing organization (CMO) is expected to come online and later in the year, a second site at the current CMO.

The demand for Wegovy^® reinforces the unmet need and has strengthened our promise to not only develop innovative medicines but to partner and advocate to change how obesity is understood, diagnosed and treated.

Although Wegovy ^® and Ozempic^® both contain semaglutide, they are different products with different indications, dosages, prescribing information, titration schedules, etc. The products are not interchangeable. 

We are aware that there are companies claiming to have availability of Wegovy^® or semaglutide. We want consumers and healthcare providers to know and be very clear that Novo Nordisk does not sell Wegovy^® (or its active ingredient, semaglutide) for the purposes of compounding with other products. We have not conducted studies to evaluate the safety and efficacy of Wegovy^® when compounded with other ingredients. Novo Nordisk is the only company that has FDA approval to market Wegovy^® and we supply it in a disposable single-use pen available by prescription only.

No, the way in which we sell and distribute our products has not changed. We distribute our products to wholesalers who supply retail pharmacies nationwide. Which pharmacies or retailers get Wegovy^® is outside of our control.

Pharmacies may experience normal delays given the time required to order the product from their local distribution center, and geographical variabilities. We encourage patients to contact their local pharmacy in advance to confirm when they will be able to fill their prescription.

We acknowledge the growing trend of weight-management telehealth providers, many of whom are advertising Wegovy^®. Novo Nordisk is not directly supplying Wegovy^® to any Telehealth providers.

Please call 1-833-4-WEGOVY (1-833-493-4689) and select option 0.